✦ LIBER ✦

9134 Phase II study of topotecan and bevacizumab in patients with metastatic non-small cell lung cancer who have failed prior systemic chemotherapy – interim analysis

✍ Scribed by Beitinjaneh, A.; Dudek, A.Z.

Book ID: 122892278
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 45 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71847-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of gefitinib v

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

✍ Kim, Seung Tae; Uhm, Ji Eun; Lee, Jeeyun; Sun, Jong-mu; Sohn, Insuk; Kim, Seon W 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 359 KB

Phase II study of tamoxifen, ifosfamide,

Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

✍ Chen, Yuh-Min; Perng, Reury-Perng; Yang, Kuang-Young; Lin, Wei-Chun; Wu, Hsiao-W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Phase II study of docetaxel and ifosfami

Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel

✍ Chen, Y 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Randomized Phase II Trial of Erlotinib W

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

✍ Witta, S. E.; Jotte, R. M.; Konduri, K.; Neubauer, M. A.; Spira, A. I.; Ruxer, R 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 917 KB

A phase II study of induction chemothera

A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis

✍ Santo, Antonio; Pedersini, R; Pasini, F; Terzi, A; Pari, F; Cartei, G; Sibau, A; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Phase 1b study results of IMO-2055, a no

Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

✍ Smith, David A.; Conkling, Paul; Richards, Donald A.; Flores, Maria Regina C.; N 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB